Aktienanalyse zu West Pharmaceutical Services Inc (WST)WSTWest Pharmaceutical Services Inc

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

West Pharmaceutical Services Inc is a good buy right now, trading at $384.02 with a strong recent performance of +4.92% over the last 5 days and a year-to-date change of +38.94%. The company has shown robust growth, with Q2 2026 sales increasing to $872 million, a 13.8% rise, and an adjusted EPS of $2.37, exceeding expectations by $0.29. However, the RSI is at 75.786, indicating it may be overbought, which is a risk to consider.

7 analysts cover WST: 4 rate it Buy, 2 Hold and 1 Sell. The average price target is 348.70.